Maternal–Neonatal Raltegravir Population Pharmacokinetics Modeling: Implications for Initial Neonatal Dosing
نویسندگان
چکیده
منابع مشابه
Cancer Therapy: Clinical Population Pharmacokinetics of Bevacizumab in Children with Osteosarcoma: Implications for Dosing
Purpose: To describe sources of interindividual variability in bevacizumab disposition in pediatric patients and explore associations among bevacizumab pharmacokinetics and clinical wound healing
متن کاملPopulation pharmacokinetics of bevacizumab in children with osteosarcoma: implications for dosing.
PURPOSE To describe sources of interindividual variability in bevacizumab disposition in pediatric patients and explore associations among bevacizumab pharmacokinetics and clinical wound healing outcomes. EXPERIMENTAL DESIGN Before tumor resection, three doses of bevacizumab (15 mg/kg) were administered to patients (median age, 12.2 years) enrolled in a multi-institutional osteosarcoma trial....
متن کاملPopulation pharmacokinetics of gentamicin and dosing optimization for infants.
The aim of this study was to characterize and validate the population pharmacokinetics of gentamicin in infants and to determine the influences of clinically relevant covariates to explain the inter- and intraindividual variabilities associated with this drug. Infants receiving intravenous gentamicin and with routine therapeutic drug monitoring were consecutively enrolled in the study. Plasma c...
متن کاملArtemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications
AIM Drug-drug interactions between antimalarial and antiretroviral drugs may influence antimalarial treatment outcomes. The aim of this study was to investigate the potential drug-drug interactions between the antimalarial drugs, lumefantrine, artemether and their respective metabolites desbutyl-lumefantrine and dihydroartemisinin, and the HIV drugs efavirenz, nevirapine and lopinavir/ritonavir...
متن کاملPharmacokinetics and dissolution of raltegravir
28 29 The pharmacokinetics of raltegravir (RAL) in HIV patients is characterised by high 30 inter/intra-patient variability. We investigated the potential contribution of the drug 31 pharmaceutical formulation on RAL pharmacokinetics. 32 We firstly compared in vivo the pharmacokinetics of RAL from 67 patients in which 33 the drug was administered by swallowing the intact tablet with those obtai...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: CPT: Pharmacometrics & Systems Pharmacology
سال: 2019
ISSN: 2163-8306,2163-8306
DOI: 10.1002/psp4.12443